Evidence map›Paper›PMID 40066587›Full record

ArticleThoracic cancer2025

Clinical Significance of Bone Metastases in Pleural Mesothelioma.

Mitsutomi Miyake, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otuski, Yoshiki Negi, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Yasuhiro Nakajima and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mitsutomi MiyakeDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Kozo KuribayashiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.ORCID https://orcid.org/0000-0002-8007-1516
Hiroshi DoiDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Aki KubotaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Taiichiro OtuskiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Yoshiki NegiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Koji MikamiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Ryo TakahashiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Akifumi NakamuraDivision of Thoracic Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan.
Yasuhiro NakajimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Daichi FujimotoDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Kazuhiro KitajimaDepartment of Radiology, Hyogo Medical University, Nishinomiya, Japan.
Toshiyuki MinamiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Takashi KijimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed to determine the incidence of BoM in PM patients and assess its prognosis and risk factors to clarify its clinical significance.

methodsA retrospective analysis was conducted on 515 histologically confirmed PM patients enrolled between January 2011 and December 2020. The cumulative incidence of BoM was calculated using the Kaplan-Meier method, with group differences assessed via log-rank tests. Risk factors for BoM were evaluated using multivariate logistic regression.

resultsThe median follow-up was 13.3 months (range: 0.2-106.7 months). BoM was detected in 59 patients (11.5%) at diagnosis or during disease progression. Multivariate analysis identified non-epithelial histology (odds ratio [OR]: 2.189, 95% confidence interval [CI]: 1.179-4.065, p = 0.013) as an independent risk factor for developing BoM. Patients with BoM had worse overall survival (OS) compared to those without BoM (median OS: 18.6 months vs. 21.7 months, p = 0.03).

conclusionsBoM in PM occurs less frequently than in primary lung cancer, with non-epithelial histology being more commonly associated with BoM. Patients with BoM had a poor prognosis, particularly when BoM was present at diagnosis. This study is limited by its retrospective design, which may introduce biases related to data collection and patient selection. Future prospective studies are needed to validate these findings.

Indexed as

Bone NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsAdultAgedAged, 80 and overClinical RelevanceFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk Factorsbone metastasiskeynote 483pleural mesotheliomaprognosisskeletal‐related events

Identifiers

PMID40066587
PMCPMC11894435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.